Supplementary Figure S9 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy

Supplementary Figure S9. CAR and SB9 expression on CD19.CAR or CD30.CAR with 4-1BB spacer (CD30.bb) TCRαβKO ATCs. A, CD19.CAR expression on TCRαβKO ATCs with or without the expression of SB9(CAS), measured by flow cytometry analysis of a representative donor (A, left) and pooled data of CD19.CAR expression (%) (A, right), where bars denote median ± SD (n = 3). B, Densitometry analysis of SB9 monomer (∼43 kDa) and calnexin (∼90 kDa) loading control of CD19.CAR TCRαβKO ATC samples on SDS-PAGE gel. The bar chart represents the median ± SD (n = 3). C, CD30.bb expression on TCRαβKO ATCs expressing different variants of SB9, measured by flow cytometry analysis of a representative donor (C, left) and pooled data of CD30.bb expression (%) (C, right), where bars denote median ± SD (n = 3). D, Densitometry analysis of SB9 monomer and calnexin loading control of CD30.bb.CAR TCRαβKO ATC samples on SDS-PAGE gel. The bar chart represents the median ± SD (n = 3).